Clinical
RSSArticles
-
Contraceptive Counseling Lacking in Southern Clinics, New Study Shows
Only one in 10 patients who received a recent positive pregnancy test reported their reproductive health provider discussed all pregnancy options at clinics in a Southern publicly funded family planning system, researchers noted. The patients whose providers mentioned all pregnancy options were more likely to rate their counseling as excellent on all items, compared with patients who did not receive information on all options. -
Pandemic Affected Family Planning, Abortions, Contraceptive Counseling
New research highlights the challenges many reproductive health providers and family planning clinics faced during the COVID-19 pandemic. These include discontinuation of services, such as placing long-acting reversible contraception and prescribing emergency contraceptive pills in advance. -
Cost to Treat U.S. Patients with Rare Diseases Likely Underestimated
NIH, FDA, other groups form consortium to speed gene therapy development.
-
Antibiotics for Appendicitis, Revisited
One year later, researchers present updated data that strengthen the alternative to surgery approach.
-
Regulators Sign Off on COVID-19 Vaccine ‘Mix and Match’
Federal agencies expand, clarify guidance on booster shots.
-
What Is the ‘Bix Rule?’
The ECG in the figure was obtained from a middle-aged man with a history of exertional chest pain and dyspnea. How would one interpret this tracing? Does the red arrow in lead II show a sinus P wave?
-
Atogepant Tablets (Qulipta)
Atogepant can be prescribed to prevent episodic migraine in adults.
-
Progression of Coronary Calcium on Statin Treatment
In those treated with statins vs. those who were not, statins decreased plaque volume in plaques with little or no calcium (plaque regression) and increased calcium density without changes in plaque volume in calcified plaques (plaque stabilization).
-
Adjuvanted Zoster Vaccine: Persistent Protection
The adjuvanted recombinant zoster vaccine efficacy is high and persistent, with apparent plateauing at > 84% four to six years after vaccination.
-
First-Line Therapy for Hypertension
When comparing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs) to treat hypertension, researchers observed no difference in major cardiovascular events — but a better safety profile for ARBs.